The approval two CAR T-cell therapies for relapsed / refractory B-cell hematological malignancies—Novatis’ Kymriah for acute lymphoblastic leukemia (ALL) and large B-cell lymphoma and Kite Pharma / Gilead’s Yescarta for large B-cell lymphoma—heralded a new era in cancer immunotherapy. Multiple myeloma, another hematological malignancy, is set to follow suit in 2021 and 2022 with the expected approval of BCMA-targeting CAR T-cell therapies, including bluebird bio/Celgene’s idecabtagene vicleucel and Janssen’s ciltacabtagene autoleucel (cilta-cel). We explore how payers approach reimbursement of CAR T-cell therapies for B-cell ALL and multiple myeloma and how reimbursement decisions impact therapy selection and prescribing among surveyed hematologist-oncologists.
· What role do CAR T-cell therapies play in the treatment of multiple myeloma and B-cell ALL?
· What are hematologist-oncologists’ experience with the use of Kyrmiah so far?
· What strategies will payers use to control utilization and costs of CAR T-cell therapies as more come to market?
· What are hematologist-oncologists’ views on select emerging CAR T-cell therapies in late-phase development?
GEOGRAPHY: United States.
PRIMARY RESEARCH: Survey of 56 U.S. hematologist-oncologists and 40 U.S. managed care organization (MCO) pharmacy directors and medical directors (PDs/MDs).
KEY DRUGS COVERED: Kymriah, Besponsa, Blincyto, Blenrep, Tecartus, idecabtagene vicleucel (ide-cel), ciltacabtagene autoleucel (cilta-cel)